Biopharmaceutical production at Roche. Actemra was first deployed in Japan when Chugai (part of the Roche Group) filed for approval for its use as a treatment for rheumatoid arthritis in adult patients and for children with SJIA.
-
Roche Pharmaceuticals' R&D facility in Basel Switzerland. -
Biopharmaceutical production at Roche. Actemra was first deployed in Japan... -
Roche's MabThera / Rituxan has recently been approved for the additional... -
Actemra is a humanised monoclonal antibody to the IL-6 receptor, inhibiting... -
Roche's MabThera / Rituxan is an anti-CD20 monoclonal antibody.
